Physician profile
Nitin Relia
NPI 1952531857
$3,780.06
in general payments reported to CMS, 2019-2025
24 companies · $937 in 2025
The $937 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $307 · 2021: $337 · 2022: $456 · 2023: $589 · 2024: $838 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,271 · Education: $92.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,271.42 |
| Education | $92.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $705.05 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $518.61 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $242.76 | 2022-2025 | |
| Ardelyx, INC. | $231.65 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Opko Pharmaceuticals, LLC | $228.07 | 2020-2025 | Rayaldee |
| Akebia Therapeutics INC | $204.17 | 2020-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $189.11 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $176.66 | 2021-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $148.53 | 2022-2025 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $146.49 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $122.81 | 2020-2025 | Terlivaz, Acthar |
| Vifor Pharma, INC. | $122.78 | 2019-2023 | Veltassa, Korsuva |
| Amgen INC. | $120.14 | 2022-2025 | Krystexxa, Repatha |
| Calliditas Therapeutics US INC. | $117.82 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.32 | 2024-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $105.35 | 2022-2025 | |
| Vantive US Healthcare LLC | $82.73 | 2025 | Renal - Pd |
| Nxstage Medical, INC. | $61.91 | 2022 | |
| Aurinia Pharma U.S., INC. | $39.39 | 2023-2024 | Lupkynis |
| Daiichi Sankyo INC. | $28.38 | 2021-2022 | |
| Mozarc Medical US LLC | $25.00 | 2025 | Argyle |
| Apellis Pharmaceuticals, INC. | $20.77 | 2025 | Empaveli |
| Horizon Therapeutics Plc | $14.50 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Relia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.